Causes of death in HIV-infected women: Persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19)

International Journal of Epidemiology

Volumn 39, Issue 1, 2010, Pages 135-146

  Hessamfar Bonarek, Mojgan ^a,b   Morlat, Philippe ^a,b,c   Salmon, Dominique ^d   Cacoub, Patrice ^e,f   May, Thierry ^g   Bonnet, Fabrice ^a,b,c   Rosenthal, Eric ^h   Costagliola, Dominique ^a,e,f   Lewden, Charlotte ^a,c   Chêne, Geneviève ^a,b,c  

^a INSERM   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d Centre Hospitalier Universitaire Cochin ^*  (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

AIDS; Causes of death; HIV infection; Women

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAUSE OF DEATH; DISEASE PREVALENCE; GENDER ISSUE; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS; RISK FACTOR; SOCIOECONOMIC CONDITIONS; WOMENS HEALTH;

ACCIDENTAL DEATH; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FRANCE; HEAD AND NECK CANCER; HEALTH CARE ACCESS; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SEX DIFFERENCE; SMOKING; SOCIOECONOMICS; SUICIDE; COMORBIDITY; DRINKING BEHAVIOR; HEALTH SURVEY; MIDDLE AGED; TIME;

FRANCE;

HUMAN IMMUNODEFICIENCY VIRUS; NICOTIANA TABACUM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ALCOHOL DRINKING; CAUSE OF DEATH; COMORBIDITY; FEMALE; HEALTH SURVEYS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; SMOKING; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 77952298865     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyp300     Document Type: Article

References (55)

1. UNAIDS. AIDS Epidemic Update 2007. http://wwwunaids.org, 2007 (date last accessed).
2. Cazein F, Lot F, Pillonel J, Pinget R, David D, Leclerc M et al. HIV and AIDS surveillance in France, 2006. Bull Epidemiol Hebd 2007;46-47:386-93.
3. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
4. Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by the Human Immunideficiency Virus (HIV) between 2000 and 2005. The "Mortalité 2000 & 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008;48:590-98.
5. Lewden C, Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005;34:121-30.
6. Palella FJ, Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34.
7. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006;145:397-406.
8. Smit C, Geskus R, Walker S et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006;20:741-49.
9. Hessol NA, Kalinowski A, Benning L et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2007;44:287-94.
10. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001;15:1115-23.
11. Patterson K, Napravnik S, Eron J, Keruly J, Moore R. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med 2007;8:406-10.
12. Sabine C. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005;19:1995-2000.
13. Garcia de la Hera M, Ferreros I, del Amo J et al. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health 2004;58: 944-50.
14. Jarrin I, Geskus R, Bhaskaran K et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008;168:532-40.
15. Nicastri E, Angeletti C, Palmisano L et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005;19:577-83.
16. Perez-Hoyos S, del Amo J, Muga R et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003;17:353-59.
17. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267-74.
18. Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 2005;19:357-70.
19. Prins M, Robertson JR, Brettle RP et al. Do gender differences in CD4 cell counts matter? AIDS 1999;13: 2361-64.
20. World Health Organisation. 10th Revision. International Classification of Diseases. Geneva: WHO, 1993.
21. Center for Diseases Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992;41:1-19.
22. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965-80.
23. Kremer H, Sonnenberg-Schwan U. Women living with HIV does sex and gender matter? A current literature review. Eur J Med Res 2003;8:8-16.
24. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002;35:313-22.
25. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002;31: 11-19.
26. Bozzette SA, Berry SH, Duan N et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998;339:1897-904.
27. Moore J, Schuman P, Schoenbaum E, Boland B, Solomon L, Smith D. Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS 1999;13:2459-68.
28. Nicastri E, Leone S, Angeletti C et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007;60: 724-32.
29. Gebo KA, Fleishman JA, Conviser R et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005;38:96-103.
30. Giordano TP, White AC Jr, Sajja P et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003;32:399-405.
31. McNaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003;32:499-505.
32. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001;344:720-25.
33. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29.
34. Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D. Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response. HIV Med 2006;7:520-29.
35. Hulgan T, Shepherd BE, Raffanti SP et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007;195:425-31.
36. Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003;32:452-61.
37. Murri R, Lepri AC, Phillips AN et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr 2003;34:184-90.
38. Lanoy E, Mary-Krause M, Tattevin P et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007;12:89-96.
39. . Late versus early testing of HIV-16 Sites, United States, 2000-2003. Morb Mortal Wkly Rep 2003;52:581-86.
40. Baratin D, Marceillac E, Trepo C et al. Characteristics of patients diagnosed with AIDS shortly after first detection of HIV antibodies in Lyon University hospitals from 1985 to 2001. HIV Med 2004;5:273-77.
41. Couturier E, Schwoebel V, Michon C et al. Determinants of delayed diagnosis of HIV infection in France, 1993-1995. AIDS 1998;12:795-800.
42. Manavi K, McMillan A, Ogilvie M, Scott G. Heterosexual men and women with HIV test positive at a later stage of infection than homoor bisexual men. Int J STD AIDS 2004;15:811-14.
43. Porter K, Wall PG, Evans BG. Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. BMJ 1993;307:20-23.
44. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 2001;15: 77-85.
45. Dray-Spira R, Lert F. Living and working with HIV in France in 2003: results from the ANRS-EN12-VESPA Study. AIDS 2007;21 (Suppl 1):S29-36.
46. Dray-Spira R, Spire B, Heard I, Lert F. Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study. AIDS 2007;21 (Suppl 1):S5-12.
47. Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr 2004;36:943-50.
48. Wood E, Montaner JS, Chan K et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002;16:2065-72.
49. Dragsted UB, Mocroft A, Vella S et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 2004;190:148-55.
50. Lewden C, Chene G, Morlat P et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-77.
51. Lewden C, Jougla E, Alioum A et al. Number of deaths among HIV-infected adults in France in 2000, threesource capture-recapture estimation. Epidemiol Infect 2006;134:1345-52.
52. Deuffic-Burban S, Costagliola D. Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000. Eur J Epidemiol 2006;21: 389-96.
53. Semaille C, Barin F, Cazein F, Pillonel J, Lot F, Brand D et al. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis 2007;196:377-83.
54. Costagliola D. [Epidemiology of HIV infection in France and Europe]. Rev Med Interne 2008;29 (Suppl 3): S266-68.
55. Aouba A, Péquignot F, Laurent F, Boileau J, Pavillon G, Jougla E. [Mortality due to HIV in France: trends since the 1980s]. Bull Epidemiol Hebd 2008;45-46:447-52.